UCB announces plans to build drug manufacturing plant in US
UCB is set to build a new biopharmaceutical plant in the US state of Georgia, the Belgian pharmaceutical group announced on Tuesday. It will be UCB's first manufacturing plant in the country.
The facility will cover nearly 43,000 square metres on a site of about 319,700 square metres. The company says the project is expected to generate an economic impact of 5 billion dollars and create 330 permanent jobs.
"The campus will be state-of-the art, using a digital-first approach by leveraging AI, robotics, and automation while being natural resources efficient," the company said in a statement. The site will produce "complex Biologics", primarily for the US market.
"This decision reflects our confidence in UCB's long-term growth and our deep-rooted commitment to the United States"
The plant will be built near Atlanta, where UCB’s US headquarters are located. Officials said the company planned to invest 2 billion dollars in the project. "This decision reflects our confidence in UCB's long-term growth and our deep-rooted commitment to the United States," said CEO Jean-Christophe Tellier.
UCB has maintained a long-standing relationship with Georgia. Earlier this year, state governor Brian Kemp visited the company’s leadership in Brussels. The company employs around 2,000 people in the US.
Headquartered in Brussels, UCB focuses on treatments for neurological and autoimmune diseases. Its portfolio includes Bimzelx, Rystiggo, Zilbrysq, Evenity and Fintepla. The company reported strong results in 2025, with profits rising by 25 per cent in the first part of the year.
© BELGA PHOTO LAURIE DIEFFEMBACQ
Related news
